Tag: meeting

SINGAPORE, June 12, 2025 (GLOBE NEWSWIRE) -- HomesToLife Ltd (Nasdaq: HTLM) (“HomesToLife” or the "Company"), a Singapore-based home furniture company with sales across Asia-Pacific, Europe and North America regions, today announced unaudited financial results for the first quarter ended March 31, 2025 (“Q1 2025”).

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

Driven by Stable Legacy Sales and Ongoing Cost Savings Initiatives

RENO, Nev., June 12, 2025 (GLOBE NEWSWIRE) -- GreetEat Corporation (OTC: GEAT) is proud to announce that it has officially filed a patent application for its innovative core technology: “Video Conferencing with Food Delivery Vouchers.” The company is now patent pending, marking a major milestone in its mission to transform the way people meet, connect, and collaborate in virtual environments.

Paris, France – June 12, 2025

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹

On 5 June 2025, the Annual General Meeting of Arco Vara AS adopted the decision to issue a targeted share offering to specific investors in order to increase the company’s share capital.
Arco Vara AS announces that the targeted share issue approved by the shareholders has been successfully completed as of 11 June 2025 – the management board has adopted a resolution to shorten the subscription period due to early subscription of issued shares. In accordance with the adopted decision of the general meeting: